Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
Abstract Immune Checkpoint Inhibitor (ICI) therapy has revolutionized treatment for advanced melanoma; however, only a subset of patients benefit from this treatment. Despite considerable efforts, the Tumor Mutation Burden (TMB) is the only FDA-approved biomarker in melanoma. However, the mechanisms...
| Published in: | Nature Communications |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-09-01
|
| Online Access: | https://doi.org/10.1038/s41467-022-32838-4 |